Denali Therapeutics Inc (DNLI)
17.21
+0.07
(+0.41%)
USD |
NASDAQ |
May 06, 10:51
Denali Therapeutics Enterprise Value: 1.409B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.409B |
| May 02, 2024 | 1.362B |
| May 01, 2024 | 1.269B |
| April 30, 2024 | 1.166B |
| April 29, 2024 | 1.189B |
| April 26, 2024 | 1.165B |
| April 25, 2024 | 1.098B |
| April 24, 2024 | 1.183B |
| April 23, 2024 | 1.262B |
| April 22, 2024 | 1.245B |
| April 19, 2024 | 1.246B |
| April 18, 2024 | 1.332B |
| April 17, 2024 | 1.363B |
| April 16, 2024 | 1.437B |
| April 15, 2024 | 1.508B |
| April 12, 2024 | 1.568B |
| April 11, 2024 | 1.698B |
| April 10, 2024 | 1.591B |
| April 09, 2024 | 1.736B |
| April 08, 2024 | 1.679B |
| April 05, 2024 | 1.729B |
| April 04, 2024 | 1.672B |
| April 03, 2024 | 1.726B |
| April 02, 2024 | 1.727B |
| April 01, 2024 | 1.895B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.888B |
| March 27, 2024 | 1.923B |
| March 26, 2024 | 1.796B |
| March 25, 2024 | 1.795B |
| March 22, 2024 | 1.759B |
| March 21, 2024 | 1.956B |
| March 20, 2024 | 1.997B |
| March 19, 2024 | 1.890B |
| March 18, 2024 | 1.826B |
| March 15, 2024 | 1.832B |
| March 14, 2024 | 1.778B |
| March 13, 2024 | 1.942B |
| March 12, 2024 | 1.923B |
| March 11, 2024 | 2.054B |
| March 08, 2024 | 1.946B |
| March 07, 2024 | 1.889B |
| March 06, 2024 | 1.888B |
| March 05, 2024 | 1.878B |
| March 04, 2024 | 1.908B |
| March 01, 2024 | 1.936B |
| February 29, 2024 | 1.782B |
| February 28, 2024 | 1.778B |
| February 27, 2024 | 2.215B |
| February 26, 2024 | 1.316B |
| February 23, 2024 | 1.321B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
902.83M
Minimum
Oct 18 2019
10.26B
Maximum
Dec 22 2020
3.067B
Average
2.542B
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics Inc | 6.225B |
| AIM ImmunoTech Inc | 7.819M |
| Perspective Therapeutics Inc | 1.055B |
| Protalix BioTherapeutics Inc | 58.97M |
| Armata Pharmaceuticals Inc | 158.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -119.47M |
| Total Expenses (Quarterly) | 132.57M |
| EPS Diluted (Quarterly) | -0.86 |
| Earnings Yield | -6.28% |
| Normalized Earnings Yield | -5.636 |